SRT3 Stock Overview
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Sartorius Aktiengesellschaft Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €273.20 |
52 Week High | €383.70 |
52 Week Low | €215.30 |
Beta | 0.84 |
1 Month Change | -28.43% |
3 Month Change | -8.93% |
1 Year Change | -21.92% |
3 Year Change | -42.58% |
5 Year Change | 67.40% |
Change since IPO | 468.87% |
Recent News & Updates
Recent updates
Shareholder Returns
SRT3 | DE Life Sciences | DE Market | |
---|---|---|---|
7D | -19.2% | -9.9% | -2.0% |
1Y | -21.9% | -14.9% | -0.3% |
Return vs Industry: SRT3 underperformed the German Life Sciences industry which returned -14.9% over the past year.
Return vs Market: SRT3 underperformed the German Market which returned -0.3% over the past year.
Price Volatility
SRT3 volatility | |
---|---|
SRT3 Average Weekly Movement | 6.6% |
Life Sciences Industry Average Movement | 6.1% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SRT3's share price has been volatile over the past 3 months.
Volatility Over Time: SRT3's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1870 | 14,614 | Joachim Kreuzburg | www.sartorius.com |
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products.
Sartorius Aktiengesellschaft Fundamentals Summary
SRT3 fundamental statistics | |
---|---|
Market cap | €16.92b |
Earnings (TTM) | €148.80m |
Revenue (TTM) | €3.31b |
126.7x
P/E Ratio5.7x
P/S RatioIs SRT3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SRT3 income statement (TTM) | |
---|---|
Revenue | €3.31b |
Cost of Revenue | €1.80b |
Gross Profit | €1.51b |
Other Expenses | €1.36b |
Earnings | €148.80m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 19, 2024
Earnings per share (EPS) | 2.16 |
Gross Margin | 45.55% |
Net Profit Margin | 4.49% |
Debt/Equity Ratio | 134.4% |
How did SRT3 perform over the long term?
See historical performance and comparison